Journal of Health Sciences and Medicine

Yazarlar: ["Selda TEKİN", "Nilufer COSKUM", "Esra ADIYEKE", "Erman ŞEN", "Ozgun TOPCUOGLU SARI", "Mücahit Uğur AYGÜN", "Ayşe ŞABABLI ÇETİN", "Fatma YILMAZ-KARADAĞ", "Nurten BAKAN"]

Konular:-

DOI:10.32322/jhsm.1176884

Anahtar Kelimeler:Vaccine,COVID-19,Elder age

Özet: Aim: The aim of our study is to reveal the factors affecting the clinical course of COVID-19 infection and mortality in immune and non-immune patients aged 65 and over. Material and Method: The study was carried out by scanning the files of a total of 1,642 COVID-19 cases aged 65 and over. The 1337 cases included in the study were divided into two groups as follows: patients who were vaccinated with the 2nd dose of CoronaVac but became infected with COVID-19 after the 14-day period in which immunization should develop (Group I) and the others who were unvaccinated, or infected with COVID-19 after a single dose of vaccination or infected after receiving a 2nd dose of vaccination in 14 days (Group II). The groups were compared with each other about mortality and the factors affecting mortality. Results: The length of intensive care unit (ICU) stay, and the total length of hospital stay were significantly longer in Group II than Group I (p<0.05). The need for mechanical ventilation (MV) and the length of MV were also significantly higher in Group II than Group I (p<0.05). All patients enrolled in the study had lung involvement. The percentage of Computed tomography (CT) involvement over 50% was statistically significant in Group II (p<0.05). The percentage of severe and critically severe patients and mortality were significantly high in Group II vs. Group I (p<0.05). Conclusion: When we compared the vaccinated and unvaccinated groups of 65 years of age, we found that hospitalization in the ICU and the need for MV increased mortality, and the vaccine reduced the need for intensive care and MV.

---